Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.
Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.
Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak.
In one line: China's answer to a viral-vector vaccine developer like J&J's Janssen unit.
Moat: narrow (IP / patents, regulatory licence). Proprietary adenovirus-vector platform and one of few Chinese firms with an approved viral-vector vaccine.
Headquarters: Tianjin, China · Employees: 1,134
Size CanSino Biologics (688185.SS) is a China Health Care company (Biotechnology) with a market value of $1.38B, the 1634th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥60.16 on 18 Nov 2026.
Performance Over six months the shares gained 0.3%, against -18.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 29.9% over the last twelve months (peer median +24.8%); the operating margin is -4.2% (peer median -296.1%).
Valuation It trades at 199.3× forward earnings against a peer median of 46.4× (most expensive of 6).
Capital Return on invested capital runs 9.5 points below its cost of capital (11.2% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.26B | CN¥1.07B | CN¥836M | CN¥349M | CN¥1.03B |
| Revenue growth | — | +28% | +139% | -66% | — |
| Gross profit | CN¥1.03B | CN¥729M | CN¥517M | -CN¥21.8M | CN¥536M |
| EBITDA | n/a | CN¥65.5M | -CN¥185M | -CN¥1.54B | -CN¥1.32B |
| Net income | CN¥29.7M | CN¥27.9M | -CN¥379M | -CN¥1.48B | -CN¥909M |
| Free cash flow | -CN¥60.9M | -CN¥108M | -CN¥536M | -CN¥1.47B | -CN¥2.82B |
| Capital expenditure | CN¥159M | CN¥244M | CN¥458M | CN¥610M | CN¥1.08B |
| Total debt | CN¥930M | CN¥1.29B | CN¥2.02B | CN¥2.71B | CN¥2.73B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CanSino Biologics 688185.SS | $1.38B | 0% | +30% | -4% | 199.3× | n/a |
| Walvax Biotechnology 300142.SZ | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Chongqing Zhifei Biological Products 300122.SZ | $5.28B | -1% | -28% | -210% | n/a | -6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688185.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.0% | -14.8% | 2nd lowest of 21 |
| 6-month return | +0.3% | -18.9% | 4th highest of 19 |
| Distance from 52-week high | -44.3% | -47.0% | 9th highest of 21 |
| Revenue growth (TTM) | +29.9% | +24.8% | 8th highest of 18 |
| Operating margin | -4.2% | -296.1% | 3rd highest of 19 |
| Forward P/E | 199.3× | 46.4× | most expensive of 6 |
| ROIC minus cost of capital | -9.5 pp | -23.7 pp | 3rd highest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 199.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |